# Lorlatinib for Newly-Diagnosed High-Grade Glioma With ROS or ALK Fusion

> **NCT06333899** · EARLY_PHASE1 · RECRUITING · sponsor: **Nationwide Children's Hospital** · enrollment: 15 (estimated)

## Conditions studied

- High Grade Glioma
- Diffuse Intrinsic Pontine Glioma
- Anaplastic Astrocytoma
- Infant Type Hemispheric Glioma
- Glioblastoma
- Glioblastoma Multiforme
- WHO Grade III Glioma
- WHO Grade IV Glioma
- Diffuse Midline Glioma, H3K27-altered

## Interventions

- **DRUG:** Lorlatinib
- **DRUG:** Lorlatinib with chemotherapy1
- **DRUG:** Lorlatinib with chemotherapy 2
- **DRUG:** Lorlatinib post Radiation

## Key facts

- **NCT ID:** NCT06333899
- **Lead sponsor:** Nationwide Children's Hospital
- **Sponsor class:** OTHER
- **Phase:** EARLY_PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-08-03
- **Primary completion:** 2029-07-01
- **Final completion:** 2035-06-01
- **Target enrollment:** 15 (ESTIMATED)
- **Last updated:** 2026-03-12

## Collaborators

- Pfizer

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06333899

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06333899, "Lorlatinib for Newly-Diagnosed High-Grade Glioma With ROS or ALK Fusion". Retrieved via AI Analytics 2026-07-20 from https://api.ai-analytics.org/clinical/NCT06333899. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*